Scott Dixon Named New Chief Commercial Officer at ObvioHealth – Executive with 20+ years of Experience

ObvioHealth, a leading global virtual research organization (VRO) delivering end-to-end decentralized clinical trials, today announces Scott Dixon as the company’s new Chief Commercial Officer. Dixon’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next generation DCT platform and app.
“ObvioHealth is empowering clinical trial sponsors to capture stronger evidence through its innovative use of technology,” said Scott Dixon. “I’m truly excited to lead our commercial and strategic partnerships, as well as our experienced service and delivery teams, to help our clients adopt ObvioHealth’s cutting-edge, digital DCT solutions.”
During his 25+ year career, Scott Dixon has integrated commercial and operational planning for life science, pharmaceutical and healthcare software companies including ERT, Oracle, Phase Forward, WebMD and Parexel. Most recently, he served as Chief Revenue Officer at Flywheel.io. His experience overseeing clinical development processes as well as direct-to-patient technology has resulted in successful breakthrough offerings for startups and Fortune 100 companies.
“We are ecstatic to bring Scott Dixon on board, and believe his multifaceted experience across operations, product and sales divisions will bring valuable expertise to ObvioHealth,” said Ivan Jarry, CEO of ObvioHealth “We look forward to his contributions to our ambitious and strategic roadmap moving forward.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”